Donepezil Zentiva

Donepezil Zentiva is a prescription medication that contains the active ingredient donepezil hydrochloride. It is supplied as oral tablets (strength not specified) and is marketed in the European Union. Donepezil belongs to the class of acetylcholinesterase inhibitors and is used to manage symptoms of mild to moderate Alzheimer’s disease by increasing acetylcholine levels in the brain. Medication is intended for administration under supervision and is not available without a prescription.

Donepezil Zentiva is indicated for the symptomatic treatment of mild to moderate Alzheimer’s disease.

- Improves cognitive function such as memory, attention, and language abilities. - Supports daily living activities by enhancing executive function. - May stabilize or modestly slow decline in neuropsychiatric symptoms. - Used as part of a comprehensive care plan that includes non‑pharmacologic interventions. - Typically prescribed when a clinician diagnoses mild to moderate Alzheimer’s disease after evaluating other treatment options. - May be combined with other symptomatic agents such as memantine when clinically appropriate. - Dosage adjustments may be considered for patients with hepatic impairment under physician guidance.

Side effects reported with Donepezil Zentiva vary in frequency and severity, and they may influence treatment adherence.

Common: - Nausea, sometimes accompanied by vomiting, especially when therapy is initiated. - Diarrhea, which may be mild to moderate in intensity. - Insomnia or vivid, abnormal dreams that can affect sleep quality. - Muscle cramps, generalized fatigue, or weakness that may limit physical activity. - Loss of appetite or weight loss, which may affect nutritional status. - Dizziness or light‑headedness, particularly when standing quickly. - Headache, which can be mild or moderate and often improves over time.

Serious: - Bradycardia or heart block, which can manifest as a markedly slow heart rate or syncope. - Significant elevations in liver enzymes, indicating possible hepatic injury.

Precautions and warnings for Donepezil Zentiva should be reviewed before initiating therapy and monitored throughout treatment.

- Assess cardiac history, especially bradyarrhythmias, before starting treatment. - Use caution in patients with hepatic impairment; dose adjustments may be required. - Monitor for gastrointestinal bleeding in individuals taking anticoagulants or NSAIDs. - Evaluate for seizures, as donepezil may lower seizure threshold. - Consider renal function; although primarily hepatic, severe renal disease may affect drug clearance. - Advise patients to report any new or worsening symptoms such as fainting, severe nausea, or jaundice.

Donepezil Zentiva can interact with several medicines; understanding these interactions helps minimize adverse effects and maintain efficacy.

Avoid: - Concurrent use with strong anticholinergic agents, which may counteract donepezil’s mechanism. - Combination with other acetylcholinesterase inhibitors, as additive cholinergic effects increase risk of toxicity. - Co‑administration with drugs that significantly prolong the QT interval. - Drugs that cause severe hypotension, such as certain antihypertensives, may worsen syncope risk.

Use with caution: - Beta‑blockers or calcium channel blockers, which may exacerbate bradycardia. - NSAIDs or anticoagulants, due to increased risk of gastrointestinal bleeding. - CYP2D6 or CYP3A4 inhibitors (e.g., fluoxetine, ketoconazole) that can raise donepezil plasma levels.